title: Multimodality imaging can predict the metabolic response of unresectable colorectal liver metastases to radioembolization therapy with Yttrium-90 labeled resin microspheres.
abstract: Selective internal radiotherapy (SIRT) using Yttrium-90 labeled resin microspheres is increasingly used for the radioembolization of unresectable liver metastases of colorectal cancer (CRC). The treatment can be simulated by scintigraphy with Tc(99m)-labeled macroaggregates of albumin (MAA). The aim of the study was to develop a predictive dosimetric model for SIRT and to validate it by correlating results with the metabolic treatment response. The simulation of the dosimetry was performed by mathematically converting all liver voxel MAA-SPECT uptake values to the absolute Y(90) activity. The voxel values were then converted to a simulated absorbed dose (Gy) using simple MIRD formalism. The metabolic response was defined as the change in total lesion glycolysis (TLG) on FDG-PET. A total of 39 metastatic liver lesions were studied in eight evaluable patients. The mean administered Y(90) activity was 1.69 GBq (range: 1.33-2.04 GBq). The median (95% CI) simulated absorbed dose (Gy) was 29 Gy (1–98 Gy) and 66 Gy(32–159 Gy) in the poor (<50% TLG change) and the good responders (TLG change > 50%),respectively [DOSAGE ERROR CORRECTED].Using a simple cut-off value of 1 for the MAA-tumor-to-normal uptake ratio, a significant metabolic response was predicted with a sensitivity of 89% (17/19), a specificity of 65% (13/20), a positive predictive value of 71% (17/24) and a negative predictive value of 87% (13/15). Integrated multimodality imaging allows prediction of metabolic response post radioembolization using Y(90)-resin microspheres, and should be used for patient selection.
authors.affiliation: Departmentof Nuclear Medicine, Bordet Institute, Bordet Institute, Université Libre de Bruxelles, Rue Héger-Bordet 1, B-1000 Brussels, Belgium. Patrick.Flamen@bordet.be
authors.forename: Patrick
authors.initials: P
authors.lastname: Flamen
authors.forename: Bruno
authors.initials: B
authors.lastname: Vanderlinden
authors.forename: Philippe
authors.initials: P
authors.lastname: Delatte
authors.forename: Ghanem
authors.initials: G
authors.lastname: Ghanem
authors.forename: Lieveke
authors.initials: L
authors.lastname: Ameye
authors.forename: Marc
authors.initials: M
authors.lastname: Van Den Eynde
authors.forename: Alain
authors.initials: A
authors.lastname: Hendlisz
mesh_terms: D000368:Aged; D017326:Clinical Trials, Phase III as Topic; D015179:Colorectal Neoplasms / Q000532:radiotherapy*; D004621:Embolization, Therapeutic; D019788:Fluorodeoxyglucose F18; D005472:Fluorouracil / Q000627:therapeutic use; D006019:Glycolysis / Q000528:radiation effects; D006801:Humans; D008113:Liver Neoplasms / Q000378:metabolism / Q000532:radiotherapy* / Q000556:secondary* / Q000601:surgery; D008863:Microspheres; D008875:Middle Aged; D008954:Models, Biological; D049268:Positron-Emission Tomography; D011829:Radiation Dosage; D015203:Reproducibility of Results; D015899:Tomography, Emission-Computed, Single-Photon; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D015021:Yttrium Radioisotopes / Q000737:chemistry / Q000627:therapeutic use*
chemical_list: D015021:Yttrium Radioisotopes; D019788:Fluorodeoxyglucose F18; D005472:Fluorouracil